Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Will Chou
Observed names:
W Chou,
W. Chou
Institution:
FibroGen (United States)
Observed institutions:
Genentech,
FibroGen (United States),
Cytokinetics (United States)
OpenAlex ID:
A5109219298
Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis
2013
·
Samya Z. Nasr
, Will Chou
, et al.
·
Journal of Medical Economics
·
47
PDF
Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients
2015
·
Gregory S. Sawicki
, Will Chou
, et al.
·
Journal of Cystic Fibrosis
·
43
PDF
Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina
2009
·
Barry H. Greenberg
, Will Chou
, et al.
·
Journal of Cardiac Failure
·
11
PDF
Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: Analysis of Medicare data
2016
·
Michael Broder
, Eunice Change
, et al.
·
European Respiratory Journal
·
5
Omalizumab and malignancy: Interim results from the EXCELS study
2011
·
Mark D. Eisner
, Mary K. Miller
, et al.
·
European Respiratory Journal
·
4
Minimal Clinically Important Differences in Radiological Changes of QLF Associated with Overall Survival in IPF: Analysis of Phase 2 Studies from FibroGen (Studies 049 and 067)
2022
·
G.H.J. Kim
, W. Chou
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
1
Minimal Clinically Important Difference of HRCT Quantitative Lung Fibrosis Scores Anchored by St. George Respiratory Questionnaire and Forced Vital Capacity in Idiopathic Pulmonary Fibrosis
2021
·
G.H.H. Kim
, W. Chou
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
1
PDF
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity
2017
·
SD Nathan
, U Costabel
, et al.
·
Thorax
·
1
PDF
S97 Annual rate of fvc decline in various patient sub-groups with idiopathic pulmonary fibrosis treated with pirfenidone: pooled analysis from 3 pivotal studies
2016
·
PW Noble
, C Albera
, et al.
·
Thorax
·
1
PDF
Quartile forced vital capacity changes at 3, 6, 9 and 12 months with pirfenidone in patients with Idiopathic Pulmonary Fibrosis: a pooled phase III analysis
2018
·
F Bonella
, R Sussman
, et al.
·
Pneumologie
Reduction in Non-Elective Respiratory-Related Hospitalizations in Patients Treated With Pirfenidone: Pooled Analyses from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis
2017
·
U Costabel
, JJ Swigris
, et al.
·
Pneumologie
P174 Effect of continued treatment with pirfenidone following a ≥10% relative decline in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF)
2016
·
AU Wells
, C Albera
, et al.
·
Thorax
PDF
P173 Reduction in non-elective respiratory-related hospitalizations in patients treated with pirfenidone: pooled analyses from three phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis
2016
·
B Ley
, JJ Swigris
, et al.
·
Thorax
PDF
Show more works
View as search
Works count:
13
Citation count:
114
H-index:
4
I10-index:
3
Year
Topic
Type